Rossmax International Ltd.

Rossmax International Ltd.

TTPEX:4121
12.75
TWD
-0.20
(-1.54%)
1.10BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
38.91
45.31
46.13
42.36
42.7
41.94
42.2
49.93
48.01
51.27
44.85
45.22
45.14
- -
Basic EPS, GAAP
0.17
-0.04
-0.38
0.27
0.37
0.22
0.35
1.84
1.35
2.01
-0.08
-0.34
-0.36
- -
Free Cash Flow per Basic Share
-0.13
-3.13
-0.24
-1.99
-1.87
-0.43
0.54
5.13
2.74
3.53
2.3
2.8
2.81
- -
Dividend per Share
0.2
- -
- -
- -
- -
0.3
0.1
0.2
1.16
1.09
1.2
0.57
- -
- -
Book Value per Share
15.3
15.51
15.06
15.06
15.39
15.19
15.16
16.91
17.14
18.28
17
17.36
17.04
16.64
Tangible Book Value per Share
13.14
13.47
13.11
14.67
15.08
14.85
14.91
16.71
16.97
18.19
16.93
17.26
16.97
16.58
Basic Weighted Avg Shares
73
74
74
74
74
74
73
74
82
85
85
85
84
83
Sales/Revenue/Turnover
2,854
3,334
3,406
3,128
3,153
3,097
3,094
3,679
3,948
4,345
3,809
3,851
3,800
- -
Operating Margin (%)
-2.52
-2.94
-3.73
-3.91
0.48
-0.25
-0.05
3.99
3.45
5.98
0.07
-1.99
-1.91
- -
Depreciation Expense
66
72
75
64
72
70
218
229
244
284
306
331
342
- -
Net Income, GAAP
13
-3
-28
20
28
17
26
135
111
170
-7
-29
-30
- -
Effective Tax Rate (%)
56.79
- -
- -
- -
44.87
39.44
35.11
14.73
20.05
20.61
95.79
- -
- -
- -
Profit Margin (%)
0.44
-0.08
-0.81
0.64
0.88
0.54
0.83
3.68
2.82
3.92
-0.17
-0.76
-0.79
- -
Working Capital
662
885
937
770
1,024
977
1,017
1,133
974
993
878
1,116
1,073
1,017
LT Debt
145
313
450
110
307
245
821
708
814
863
990
1,017
997
963
Total Equity
1,361
1,466
1,383
1,337
1,352
1,341
1,331
1,660
1,779
1,944
1,851
2,089
1,984
1,911
Return on Invested Capital (%)
-2.09
- -
- -
- -
0.48
-0.26
0.47
5.02
3.91
6.86
0.01
- -
- -
- -
Return on Capital (%)
1.12
- -
- -
- -
2.33
1.48
2.03
5.44
4.07
4.78
-0.41
- -
- -
- -
Return on Common Equity (%)
1.13
-0.24
-2.46
1.81
2.46
1.47
2.3
11.01
7.99
11.36
-0.44
-2.01
-2.07
- -

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
345
344
310
LT Borrowings
187
235
232
LT Finance Leases
811
797
731
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
83
83
83
Market Capitalization
1,291
1,307
1,105

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,245
2,083
2,091
Cash, Cash Equivalents & STI
839
704
701
Accounts Receivable, Net
225
226
244
Inventories
1,022
1,012
1,023
Total Current Liabilities
1,172
1,058
1,074
Payables & Accruals
- -
- -
- -
ST Debt
345
344
310
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.04%
3.9%
-5.02%
Free Cash Flow
125.65%
-4.17%
-0.75%
Net Income, GAAP
58.02%
54.68%
1.87%
Sales/Revenue/Turnover
1.45%
0.96%
-1.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
951
957
974
970
3,851
2025
926
982
- -
951
3,800
2026
938
947
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
-0.09
-0.14
-0.16
-0.34
2025
-0.12
-0.06
- -
-0.08
-0.36
2026
-0.11
-0.2
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.57
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Chih Ping Liu
Full Time Employees
350
Sector
Distribution services
Industry
Medical distributors
Address
No. 189, Kang Chien Road Taipei TP Taiwan 114
IPO Date
Nov 28, 2002
Business
Rossmax International Ltd. (4121.TWO) develops, manufactures and supplies healthcare products and solutions focused on prevention, monitoring and therapy for chronic conditions including hypertension, diabetes, respiratory diseases, fever management, obesity, wound healing and sleep disorders. The company offers an extensive portfolio encompassing blood pressure monitors featuring PARR Technology for arrhythmia detection, Artery Check Technology pulse oximeters, blood glucose monitoring systems with advanced GDH-FAD technology, non-contact telephoto and infrared ear thermometers with Thermocal calibration, body fat monitors and scales, nebulizers incorporating 3BREATH 3-in-1 respiratory solutions with mesh and valve adjustable technologies, suction units, peak flow meters, sphygmomanometers, stethoscopes, fitness products, hot and pain therapy devices, and the Rossmax healthstyle app for Bluetooth-enabled tracking of blood pressure, glucose, SpO2, weight and temperature; in 2024, it launched the BP5 electric breast pump expanding into kids health solutions. Founded in 1988 and headquartered in Taipei, Taiwan, with a fully integrated production facility in Shanghai, China, Rossmax operates subsidiaries including Rossmax Swiss, Rossmax India and Rossmax Japan, and distributes products across more than 90 countries such as Taiwan, Italy, Brazil, Mainland China, Germany, Ukraine, Poland, Iraq, India, the United Kingdom, Japan, Turkey and others. Recent developments include submission of MDR application in 2025 for enhanced regulatory compliance in Europe, completion of a share buyback program in April 2025 repurchasing 1.45% of shares, introduction of e-commerce and online shop initiatives in 2021-2022 followed by the Rossmax Online Academy in 2023, and ongoing participation in global trade shows like Medica 2025 to showcase innovations.